CILP

Across TCGA pan-cancer cohorts, CILP mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CILP data layer compared with 18 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CILP mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CILP expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where CILP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	All	0.505	0.854	.001	25	view →
PDAC	OS	Quartile	III,IV	0.195	0.645	.003	22	view →
LUAD	DFS	Tertile	II,III,IV	0.981	0.730	.007	13	view →
COAD	DFS	Median	III,IV	0.898	1.000	.047	6	view →
CCRCC	OS	Median	All	0.916	0.660	.040	1	view →
HNSC	DFS	Quartile	III,IV	0.821	0.609	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CILP–LSCC (DFS)

Open the LSCC breakdown →